J Refract Surg. 2021 Jan 1;37(1):7-15. doi: 10.3928/1081597X-20201013-04.
To compare the 2-year visual and refractive outcomes with the Eyecryl Phakic Toric IOL (EP TIOL) (Biotech Vision Care Pvt Ltd) and Visian Toric ICL (TICL) (STAAR Surgical) for correction of high myopic astigmatism.
This prospective, interventional, non-randomized comparison study included eligible patients who underwent toric phakic IOL surgery in one or both eyes with either the EP TIOL or TICL for myopic astigmatism. Two years postoperatively, both lenses were compared for their safety, efficacy, stability, and patient satisfaction. Vector analysis of astigmatism was performed using the Alpins method with the ASSORT software (ASSORT Party Ltd).
A total of 50 eyes were included, of which 25 eyes received EP TIOL implantation and the remaining 25 received TICL implantation. Preoperative mean ± standard deviation of spherical equivalent (SE) and cylinder was -10.15 ± 4.04 and -2.08 ± 0.86 diopters (D) in the EP TIOL group and -10.21 ± 3.97 and -2.17 ± 0.95 D in the TICL group, respectively. At 2 years of follow-up, there was no significant difference between the mean uncorrected distance visual acuity, corrected distance visual acuity, spherical equivalent, and residual astigmatism between the two groups (P > .05 for all parameters). Ninety-two percent of eyes in the EP TIOL group and 88% of eyes in the TICL group were within ±0.50 D of refractive astigmatism. Vector analysis of astigmatism showed a comparable Correction Index of 0.98 in the EP TIOL group and 0.94 in the TICL group, signifying a mild undercorrection of 2% and 6%, respectively. Two eyes in the TICL group underwent exchange for high vault and one eye required realignment due to significant postoperative rotation.
At least for the first 2 years postoperatively, both toric phakic IOLs were safe and effective in managing high myopic astigmatism with comparable visual results and patient satisfaction. [J Refract Surg. 2021;37(1):7-15.].
比较 EyeCryl Phakic Toric IOL（EP TIOL）（Biotech Vision Care Pvt Ltd）和 Visian Toric ICL（TICL）（STAAR Surgical）治疗高度近视散光的 2 年视觉和屈光结果。
这项前瞻性、干预性、非随机比较研究纳入了符合条件的患者，他们在一只或两只眼中接受了 Toric 有晶状体眼人工晶状体手术，分别使用 EP TIOL 或 TICL 治疗近视散光。术后 2 年，比较两种晶状体的安全性、有效性、稳定性和患者满意度。使用 ASSORT 软件（ASSORT Party Ltd）的 Alpins 方法对散光进行向量分析。
共纳入 50 只眼，其中 25 只眼植入 EP TIOL，其余 25 只眼植入 TICL。EP TIOL 组术前平均（标准差）等效球镜度（SE）和柱镜度分别为-10.15（4.04）和-2.08（0.86）屈光度（D），TICL 组分别为-10.21（3.97）和-2.17（0.95）D。随访 2 年时，两组间平均未矫正远视力、矫正远视力、SE 和残余散光无显著差异（所有参数 P＞0.05）。EP TIOL 组 92%的眼和 TICL 组 88%的眼屈光度散光在±0.50 D 以内。散光的向量分析显示，EP TIOL 组的矫正指数为 0.98，TICL 组为 0.94，分别表示 2%和 6%的轻微欠矫。TICL 组中有 2 只眼因高拱需要更换，1 只眼因术后明显旋转需要重新定位。
至少在术后 2 年内，两种 Toric 有晶状体眼人工晶状体治疗高度近视散光均安全有效，视觉效果和患者满意度相当。[J Refract Surg. 2021;37(1):7-15.]。
